Last reviewed · How we verify
ICP-488
ICP-488 is a tyrosine kinase inhibitor that targets FLT3 and other kinases involved in hematologic malignancies.
ICP-488 is a tyrosine kinase inhibitor that targets FLT3 and other kinases involved in hematologic malignancies. Used for Acute myeloid leukemia with FLT3 mutations.
At a glance
| Generic name | ICP-488 |
|---|---|
| Sponsor | Beijing InnoCare Pharma Tech Co., Ltd. |
| Drug class | FLT3 inhibitor |
| Target | FLT3 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
ICP-488 selectively inhibits FLT3 (FMS-like tyrosine kinase 3) and related kinase pathways that drive proliferation in acute myeloid leukemia and other hematologic cancers. By blocking these oncogenic signaling pathways, the drug aims to suppress leukemic cell growth and induce apoptosis in FLT3-mutated or FLT3-ITD positive disease.
Approved indications
- Acute myeloid leukemia with FLT3 mutations
Common side effects
- Nausea
- Diarrhea
- Vomiting
- Fatigue
- Hematologic toxicity
Key clinical trials
- Evaluate the Efficacy and Safety of ICP-488 in Subjects With Cutaneous Lupus Erythematosus (CLE) Double-blind Study (PHASE2)
- Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis (PHASE3)
- Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients with Moderate to Severe Plaque Psoriasis (PHASE2)
- A Clinical Study of ICP-488 in Healthy Subjects and Patients With Psoriasis (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ICP-488 CI brief — competitive landscape report
- ICP-488 updates RSS · CI watch RSS
- Beijing InnoCare Pharma Tech Co., Ltd. portfolio CI